These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23940871)

  • 1. Part D's underuse of generics wastes $1B per year.
    Manag Care; 2013 Jul; 22(7):68. PubMed ID: 23940871
    [No Abstract]   [Full Text] [Related]  

  • 2. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
    Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
    Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
    Feldman WB; Rome BN; Lehmann LS; Kesselheim AS
    JAMA Intern Med; 2020 Apr; 180(4):597-601. PubMed ID: 32011624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best buy drugs: many common generics beat brand names.
    Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454
    [No Abstract]   [Full Text] [Related]  

  • 5. Bexarotene: A Case Study of Medicare Part D's Specialty Drug Shortcomings.
    Puri P; Rajkumar SV; Shah ND; Pittelkow MR; Mangold AR
    Mayo Clin Proc; 2021 Oct; 96(10):2519-2522. PubMed ID: 34531065
    [No Abstract]   [Full Text] [Related]  

  • 6. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare Part D payments for neurologist-prescribed drugs.
    De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
    Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in use of high-cost diabetes mellitus medications in the VA healthcare system.
    Gellad W; Mor M; Zhao X; Donohue J; Good C
    Arch Intern Med; 2012 Nov; 172(20):1608-9. PubMed ID: 23044980
    [No Abstract]   [Full Text] [Related]  

  • 9. Part D coverage gap and adherence to diabetes medications.
    Gu Q; Zeng F; Patel BV; Tripoli LC
    Am J Manag Care; 2010; 16(12):911-8. PubMed ID: 21348561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
    Sacks NC; Burgess JF; Cabral HJ; Pizer SD
    Health Econ; 2017 Jun; 26(6):753-764. PubMed ID: 27150938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of insulin patents and market exclusivities in the USA.
    Luo J; Kesselheim AS
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):835-7. PubMed ID: 26453281
    [No Abstract]   [Full Text] [Related]  

  • 12. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D.
    DeJong C; Masuda C; Chen R; Kazi DS; Dudley RA; Tseng CW
    JAMA Intern Med; 2020 Dec; 180(12):1696-1699. PubMed ID: 32926091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D.
    Trish E; Kaiser K; Joyce G
    JAMA Netw Open; 2021 Jan; 4(1):e2033988. PubMed ID: 33496792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drugs. Does inexpensive mean cheap?
    Dinsmoor RS
    Diabetes Self Manag; 2004; 21(1):8-10, 12. PubMed ID: 15025019
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug cost-sharing amounts stable 2010-2011.
    Manag Care; 2012 Jan; 21(1):59. PubMed ID: 22334940
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care.
    Piette JD; Wagner TH; Potter MB; Schillinger D
    Med Care; 2004 Feb; 42(2):102-9. PubMed ID: 14734946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.
    Neuman P; Strollo MK; Guterman S; Rogers WH; Li A; Rodday AM; Safran DG
    Health Aff (Millwood); 2007; 26(5):w630-43. PubMed ID: 17711865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.